Product Description
Ondansetron is one of the medications most commonly used for empiric treatment of nausea and vomiting. Ondansetron has extreme utility as an antiemetic drug, and it is effective against nausea and vomiting of various etiologies. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/29763014/)
Mechanisms of Action: 5-HT3 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Oncology Unspecified | Oncology Unspecified | Oncology Unspecified
Known Adverse Events: Headache | Constipation | Diarrhea | Long QT Syndrome | Myocardial Ischemia | Spasm | Morphine Dependence | Serotonin Syndrome | Ileus | Intestinal Obstruction | Anaphylaxis | Drug Hypersensitivity | Cardiac Arrhythmias | Abnormalities, Radiation-Induced | Skin Abnormalities | Pregnancy Outcomes | Pregnancy, Abdominal | Hypoxia
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Bulgaria, Croatia, Estonia, Finland, Latvia, Poland, Sweden, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Alcoholism
Phase 2: Alzheimer Disease|Muscle Weakness|Myasthenia Gravis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ADVANCE-AD04-001 | P2 |
Unknown Status |
Alzheimer Disease |
2026-12-31 |
|
| DAS-001-001 | P2 |
Recruiting |
Myasthenia Gravis|Muscle Weakness |
2025-07-30 |
|
| 2022-003532-73 | P2 |
Active, not recruiting |
Alzheimer Disease |
2025-01-24 |
|
| 2019-000737-39 | P3 |
Completed |
Alcoholism |
2022-03-18 |